BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 32721094)

  • 1. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
    Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
    Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study.
    Sueoka-Aragane N; Katakami N; Satouchi M; Yokota S; Aoe K; Iwanaga K; Otsuka K; Morita S; Kimura S; Negoro S;
    Cancer Sci; 2016 Feb; 107(2):162-7. PubMed ID: 26577492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Profiling of Non-Small Cell Lung Cancer at Development of Resistance to First- or Second-Generation EGFR-TKIs by CAPP-Seq Analysis of Circulating Tumor DNA.
    Otsubo K; Sakai K; Takeshita M; Harada D; Azuma K; Ota K; Akamatsu H; Goto K; Horiike A; Kurata T; Nakagaki N; Nosaki K; Iwama E; Nakanishi Y; Nishio K; Okamoto I
    Oncologist; 2019 Aug; 24(8):1022-1026. PubMed ID: 31023862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 6. EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291.
    Thress KS; Brant R; Carr TH; Dearden S; Jenkins S; Brown H; Hammett T; Cantarini M; Barrett JC
    Lung Cancer; 2015 Dec; 90(3):509-15. PubMed ID: 26494259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).
    Lee JY; Qing X; Xiumin W; Yali B; Chi S; Bak SH; Lee HY; Sun JM; Lee SH; Ahn JS; Cho EK; Kim DW; Kim HR; Min YJ; Jung SH; Park K; Mao M; Ahn MJ
    Oncotarget; 2016 Feb; 7(6):6984-93. PubMed ID: 26755650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
    Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
    Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of EGFR mutations in patients with non-small cell lung cancer by high resolution melting. Comparison with other methods.
    Martínez-Carretero C; Pascual FI; Rus A; Bernardo I
    Clin Chem Lab Med; 2017 Oct; 55(12):1970-1978. PubMed ID: 28432840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Digital PCR analysis of plasma cell-free DNA for non-invasive detection of drug resistance mechanisms in EGFR mutant NSCLC: Correlation with paired tumor samples.
    Ishii H; Azuma K; Sakai K; Kawahara A; Yamada K; Tokito T; Okamoto I; Nishio K; Hoshino T
    Oncotarget; 2015 Oct; 6(31):30850-8. PubMed ID: 26334838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of
    Bai H; Xia J; Zhao X; Gong Z; Zhang D; Xiong L
    J Clin Pathol; 2019 May; 72(5):379-385. PubMed ID: 30787028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
    He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
    Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
    Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
    Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The "COLD-PCR approach" for early and cost-effective detection of tyrosine kinase inhibitor resistance mutations in EGFR-positive non-small cell lung cancer.
    Mairinger FD; Vollbrecht C; Streubel A; Roth A; Landt O; Walter HF; Kollmeier J; Mairinger T
    Appl Immunohistochem Mol Morphol; 2014; 22(2):114-8. PubMed ID: 24517913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of plasma EGFR mutations for personalized treatment of lung cancer patients without pathologic diagnosis.
    Deng Q; Fang Q; Sun H; Singh AP; Alexander M; Li S; Cheng H; Zhou S
    Cancer Med; 2020 Mar; 9(6):2085-2095. PubMed ID: 31991049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
    Iwama E; Sakai K; Azuma K; Harada D; Nosaki K; Hotta K; Nishio M; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
    Cancer Sci; 2018 Dec; 109(12):3921-3933. PubMed ID: 30289575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
    Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
    Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC.
    Wang Z; Chen R; Wang S; Zhong J; Wu M; Zhao J; Duan J; Zhuo M; An T; Wang Y; Bai H; Wang J
    PLoS One; 2014; 9(11):e110780. PubMed ID: 25405807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.